OakChart

NovaBridge Biosciences ADR

NBPHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

0.8610+0.0009 (0.10%)
2026-11-12 01:50 CET
Market cap
99.77 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-37.95 USD m
Free cash flow, TTM
-33.31 USD m
EPS diluted, TTM
-0.33
P/E
-
Compare

Price

NBP against its 20, 50 and 200-day averages
2050200earnings
1.002.003.003.3M6.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NBPclose 0.8620-day 1.1550-day 1.37200-day 2.070.86

83.4% under the 52-week high of 5.19 on 6 Jan 2026. 52-week low 0.85 on 11 Nov 2026. Last 15 sessions, 63.5% high to low

Volume 0.86× normal · the line is the 50-bar volume average

Profile

NBP
52-week range, 0% of the way up
0.865.19

NovaBridge Biosciences operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.

Employees30
IPOJan 17, 2020
Beta1.75
ATR, 14d0.08
Rel volume0.86
Short float3.65%
Insider own15.47%
Inst own19.60%

Snapshot

6 groups

Valuation

Index-
Market Cap99.88M
Enterprise Value-86.51M
Income-46.44M
Sales0.00M
Book/sh1.73
Cash/sh1.65
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees30
IPOJan 17, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.50
P/C0.52
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.64
Current Ratio7.64
Debt/Eq0.02
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.44
EPS next Y-0.62
EPS next Q-0.18
EPS this Y-146.03%
EPS next Y-20.65%
EPS next 5Y-
EPS past 3/5Y52.47% -
Sales past 3/5Y- -
EPS Y/Y TTM37.90%
Sales Y/Y TTM-
EPS Q/Q-112.22%
Sales Q/Q-100.00%
EarningsAug 20 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own15.47%
Insider Trans-0.87%
Inst Own19.60%
Inst Trans-5.65%
ROA-
ROE-
ROIC-22.73%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-25.19%
SMA50-36.97%
SMA200-58.38%
Trades-

Technical

Shs Outstand115.38M
Shs Float98.05M
Short Float3.65%
Short Ratio7.69
Short Interest3.58M
52W High5.19 -83.41%
52W Low0.86 0.12%
Volatility7.52% 7.53%
ATR (14)0.08
RSI (14)20.87
Beta1.75
Rel Volume0.86
Avg Volume465.37K
Volume400,340

Performance

Perf Week-14.75%
Perf Month-33.26%
Perf Quarter-54.68%
Perf Half Y-58.00%
Perf YTD-78.37%
Perf Year-79.65%
Perf 3Y-45.16%
Perf 5Y-98.59%
Perf 10Y-
Recom1.00
Target Price8.67
Prev Close0.86
Price0.86
Change %0.10%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Feb 06, 2026ResumedHH.C. WainwrightBuy$7 → $9+945.3%
Oct 03, 2025InitiatedLLeerink PartnersOutperform$9+945.3%
Sep 09, 2025InitiatedBBTIG ResearchBuy$7+713.0%
Dec 09, 2021InitiatedSSiebert Williams ShankBuy$96+11,049.8%
Jun 02, 2021InitiatedDDaiwa SecuritiesBuy
Mar 15, 2021InitiatedNNeedhamBuy$75+8,610.8%
Mar 03, 2021ReiteratedHH.C. WainwrightBuy$55 → $75+8,610.8%
Feb 25, 2021InitiatedPPiper SandlerOverweight$75+8,610.8%
Dec 07, 2020InitiatedHH.C. WainwrightBuy$55+6,287.9%
Jul 27, 2020InitiatedCCantor FitzgeraldOverweight$50+5,707.2%

Peers

Mkt cap
TickerCompanyMkt cap
ALXOAlx Oncology Holdings Inc154.87M
KLRSKalaris Therapeutics Inc41.50M
EYPTEyePoint Inc30.74M
ZYMEZymeworks BC Inc2.02B
CMPXCompass Therapeutics Inc149.51M
ADAGAdagene Inc ADR143.01M
KODKodiak Sciences Inc6.87B
CGENCompugen Ltd197.98M
OCULOcular Therapeutix Inc1.47B
GMABGenmab ADR33.13B

Insider trading

14 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Dennis Phillip AndrewChief Medical OfficerSep 18 '26Sale0.718,2095,828173,427Sep 21 04:05 PM
Dennis Phillip AndrewChief Medical OfficerSep 18 '26Proposed Sale1.623,5695,799Sep 18 11:57 AM
Cao Sean WuxiongChief Bus. Development OfficerSep 09 '26Sale0.74107,97879,904266,467Sep 11 04:30 PM
Cao Sean WuxiongOfficerSep 09 '26Proposed Sale1.6946,94779,378Sep 09 02:48 PM
Xu Cong ClaireEVP, Clinical DevelopmentAug 31 '26Sale0.793,2822,593304,201Sep 01 06:00 PM
Xu Cong ClaireSVP, Clinical DevelopmentJul 06 '26Sale0.894,4853,992298,101Jul 07 07:50 PM
Dennis Phillip AndrewChief Medical OfficerJun 18 '26Sale0.668,4945,606157,941Jun 22 05:23 PM
Xu Cong ClaireSVP, Clinical DevelopmentJun 01 '26Sale3.943,49413,766290,154Jun 02 06:46 PM
Cao Sean WuxiongSee RemarksMay 14 '26Sale1.9921,39942,58435,073May 18 04:05 PM
Cao Sean WuxiongOfficerMay 14 '26Proposed Sale1.999,30418,534May 14 02:50 PM
Hagler Mark ArnoldSee RemarksApr 24 '26Buy2.51230,000577,300230,000Apr 28 04:05 PM
Dennis Phillip AndrewChief Medical OfficerMar 18 '26Proposed Sale2.793,63810,153Mar 18 04:08 PM
Skelton Joseph W.OfficerJan 02 '26Proposed Sale4.33120,000519,600Jan 02 04:00 PM
Dennis Phillip AndrewCHIEF MEDICAL OFFICERDec 18 '25Proposed Sale4.233,43114,501Dec 18 11:30 AM

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
SPEMState Street SPDR Portfolio Emerging Markets ETFAUM: 16.35B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
GXCState Street SPDR S&P China ETFAUM: 441.93M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 100
  • NovaBridge Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer (GlobeNewswire)
  • NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development (GlobeNewswire)
  • Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia (GlobeNewswire) +9.62%
  • Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis (GlobeNewswire)
  • NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026 (GlobeNewswire)
  • NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director (GlobeNewswire)
  • NovaBridge Biosciences to Participate in September Investor Conferences (GlobeNewswire)
  • NovaBridge Biosciences (NBP) (H1 2026) Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
  • NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution (GlobeNewswire)
  • NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026 (GlobeNewswire)
  • NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026 (GlobeNewswire)
  • NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer (GlobeNewswire) +20.73%
  • NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-08-20-0.140--0.00--
2026Q12026-05-14-0.110-0.110-0.0300.000.002
2025Q42026-04-07-0.220-0.035-0.0300.000.002
2025Q32025-11-13-0.025-0.093-0.0680.000.006
2025Q22025-08-20-0.030-0.054-0.0680.000.005
2025Q12025-05-15-0.020-0.063-0.0390.000.003
2024S22025-04-03-0.050-0.060-0.9141.18-1
2024S12024-08-280.040--0.3041.18--
2024Q12024-05-29-0.220-0.220-0.2200.000.001
2023S22024-03-14-0.402-0.690-1.2431.180.002
2023Q22023-08-17-0.556-1.310-0.5532.700.001
2023Q12023-05-31-0.140-0.140-0.2790.000.002
2022Q42023-03-31-1.010-0.850--43.9035.001
2022Q32023-01-11-0.464--0.4640.00-2
2022Q22022-08-30-0.990-1.243-7.7017.502
2022Q12022-08-09-0.454--0.4540.00-1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-28.900-21.490-3.6944.317.98
2020FY0.7530.5310.998237183.04
2021FY-2.090-2.469-4.75913.8177.78
2022FY-2.416-2.145-4.513-32.6945.67
2023FY-1.010-1.628-2.4943.893.71
2024FY-0.120-0.173-0.6970.000.00
2025FY-0.210-0.110-0.2100.000.00
2026FY--0.517--0.00
2027FY--0.623--0.00
2028FY--0.587--0.00
2029FY--0.570--12.12
2030FY--0.400--54.75

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2S2026-10-301000.000.000.00
2026S2E2026-10-30100-0.19-0.19-0.19
2026S2E2025-10-22110-0.03-0.03-0.03
2026S2E2025-10-21110-0.03-0.03-0.03
2026S2E2025-10-20110-0.03-0.03-0.03
2026S2E2025-10-19110-0.03-0.03-0.03
2026S2E2025-10-18110-0.03-0.03-0.03
2026S2E2025-10-17110-0.03-0.03-0.03
2026S2E2025-10-16110-0.03-0.03-0.03
2026S2E2025-10-15110-0.03-0.03-0.03
2026S2E2025-10-14110-0.03-0.03-0.03
2026S2E2025-10-13110-0.03-0.03-0.03
2026S2E2025-10-12110-0.03-0.03-0.03
2026S2E2025-10-11110-0.03-0.03-0.03

Estimate history

EPS, annual-0.759-1.047-3.6940.998-4.759-4.513-2.494-0.697-0.484
Period201720182019202020212022202320242025
EPS, quarterly-0.039-0.068-0.068-0.268
PeriodQ1 '25Q2 '25Q3 '25Q4 '25
Sales, annual1.718.1284.342223.50313.649-32.9040.63100
Period201720182019202020212022202320242025
Sales, quarterly0000
PeriodQ1 '25Q2 '25Q3 '25Q4 '25
Shares, annual58.17258.17258.17271.69179.92582.27377.02378.622115.382
Period201720182019202020212022202320242025
Shares, quarterly78.94179.192115.291115.382
PeriodQ1 '25Q2 '25Q3 '25Q4 '25

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.63-32.9013.65223.504.348.13
Cost of Goods Sold Incl. D&A0.600.860.987.1313.0512.09---
Gross Profit-0.60-0.86-0.98-3.23-45.951.56---
Selling, General and Administrative Excl. Other40.2393.6650.4725.48246.53322.72197.71214.1773.40
Research and Development14.3663.0721.7821.43134.38188.07142.66121.6364.38
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-40.83-94.52-51.45-48.93-292.48-321.1622.54-212.01-66.29
Interest Expense0.000.000.000.000.000.000.140.431.77
Unusual Expense0.000.00-13.8624.14-3.08-7.29-61.132.41-4.44
Net Income Before Taxes-37.95-88.57-48.68-70.75-307.28-304.9685.73-210.13-60.62
Income Taxes0.000.000.000.000.10-0.491.770.000.26
Consolidated Net Income-37.95-88.57-49.72-82.15-372.35-361.5268.23-210.13-60.88
Net Income From Continuing Operations-37.95-46.39-49.72-82.15-372.35-361.5268.23-210.13-60.88
Net Income-37.95-46.39-56.62-207.55-372.35-361.5268.23-214.91-60.88
EPS (Recurring)-0.33-0.48-0.39-2.29-4.54-4.830.37-3.67-1.10
EPS (Basic, Before Extraordinaries)-0.33-0.48-0.70-2.49-4.51-4.761.17-3.69-1.05
EPS (Diluted)-0.33-0.48-0.70-2.49-4.51-4.761.00-3.69-1.05
EBITDA-40.23-93.66-50.47-24.85-283.47-316.2725.79-209.83-65.27
Non-Operating Income (Expense)2.885.94-11.092.32-17.888.922.204.733.00
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.984.49-1.467.6782.64144.6453.6255.920.40
Price To Sales Ratio---250.43-263.7414.42--
Gross Margin----511.77139.6611.41---
Operating Margin----7,749.36888.90-2,353.0610.08-4,883.23-815.60
Net Margin----32,868.491,131.65-2,648.7030.53-4,950.00-749.02
Shares Outstanding116.00115.3878.6277.0282.2779.9271.6958.1758.17
Market Capitalization99.7799.7765.47155.62347.353,647.263,323.872,989.72-

Income statement, quarterly

Currency USD, millions
Metric2026S12024S12023S22023S12022S12021S22021S1
Total Revenue0.00-0.001.102.848.0010.922.75
Cost of Goods Sold Incl. D&A0.60-0.00-0.006.157.22-
Gross Profit-0.60-0.00-2.841.863.70-
Selling, General and Administrative Excl. Other40.23-25.0779.0699.76128.46166.13161.48
Research and Development14.36-10.7750.3264.4169.8496.4091.68
Other Operating Expense0.00-0.000.000.000.000.000.00
Operating Income-40.83--25.07-77.96-96.92-126.60-162.43-158.73
Interest Expense0.00-0.000.070.030.000.000.00
Unusual Expense0.00--22.460.00-1.09-7.310.00
Net Income Before Taxes-37.95--16.76-92.91-102.90-133.60-155.71-149.25
Income Taxes0.00-0.000.000.000.00-0.00-0.48
Consolidated Net Income-37.95--17.80-95.73-111.50-161.53-195.15-166.43
Net Income From Continuing Operations-37.95--17.80-95.73-111.50-161.53-195.15-166.43
Net Income-37.95--24.56-95.73-111.50-161.53-195.15-166.43
EPS (Recurring)-0.33-0.09-1.04-1.34-1.98-2.56-2.27
EPS (Basic, Before Extraordinaries)-0.33--0.30-1.24-1.34-1.97-2.49-2.27
EPS (Diluted)-0.33--0.30-1.24-1.34-1.97-2.49-2.27
EBITDA-40.23-----124.66--
Non-Operating Income (Expense)2.88-8.317.57-5.94-8.09-0.599.48
Stock Option Compensation Expense0.98-2.806.1414.9922.79106.0138.81
Price To Sales Ratio--122.3637.15-49.03271.41-
Gross Margin----100.0023.2033.91-
Operating Margin----7,062.80-3,417.82-1,582.12-1,486.94-5,776.19
Net Margin----8,673.15-3,931.80-2,018.70-1,786.54-6,056.15
Shares Outstanding116.00-77.0277.0281.9083.1079.9276.96
Market Capitalization99.77-128.63155.62246.00932.773,647.266,316.56

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments210.84173.40311.73510.12671.04732.49175.90276.23104.26
Short Term Receivables1.791.171.834.7860.9671.248.029.360.63
Inventories0.000.000.000.004.270.000.000.000.00
Other Current Assets4.892.1216.356.7713.9913.3711.5111.081.31
Total Current Assets217.52176.69329.91521.67750.27817.10195.43296.67106.20
Net Property, Plant & Equipment2.953.805.5517.8324.876.166.684.033.43
Total Investments and Advances37.2430.820.004.4455.25101.660.000.000.00
Intangible Assets--16.6540.4944.2843.2844.7145.3647.82
Other Assets2.811.3633.461.574.180.312.630.000.00
Total Assets260.52212.68368.92586.00878.85968.50249.45346.06157.45
Short Term Debt Incl. Current Port. of LT Debt0.890.820.636.174.811.238.1611.6515.20
Accounts Payable0.000.000.000.000.000.000.000.000.00
Other Current Liabilities26.007.6457.52102.8993.1086.8676.3338.7714.76
Total Current Liabilities26.898.4558.14109.0697.9188.1084.4850.4229.97
Long Term Debt2.183.073.264.6112.830.85456.50434.39126.58
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.510.0064.9353.7352.7019.110.000.000.00
Total Liabilities29.5811.52126.34167.41163.44108.05540.99484.81156.55
Non-Equity Reserves0.000.000.000.000.000.000.560.360.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity230.94201.16242.58418.59715.41860.45-292.10-139.11-46.04
Total Shareholders Equity230.94201.16242.58418.59715.41860.45-292.10-139.11-46.04
Accumulated Minority Interest0.000.000.000.000.000.000.000.0046.95
Total Equity230.94201.16242.58418.59715.41860.45-292.10-139.110.91
Total Liabilities & Stockholders Equity260.52212.68368.92586.00878.85968.50249.45346.06157.45
Book Value Per Share2.002.563.155.098.9512.00-5.02-2.39-0.79
Tangible Book Value Per Share2.002.563.154.608.4011.40-5.79-3.17-1.61
Full-Time Employees303222031837822818513459
Price to Book Ratio0.500.280.460.585.293.935.15--
Return on Assets-19.61-17.11-17.20-50.84-39.1411.20-70.57-24.18-
Return on Equity-21.47-22.43-24.85-65.67-45.8824.01---
Return on Invested Capital-19.90-27.73-84.42-87.98-49.647.92-127.81-20.62-54.79
Quick Ratio8.0920.905.674.787.629.282.315.883.54
Current Ratio8.0920.905.674.787.669.282.315.883.54

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-37.95-88.57-49.72-82.15-372.35-361.5268.23-210.13-60.88
Depreciation0.600.860.9824.089.485.293.352.261.02
Other Funds (Non Cash)10.1449.94-1.1422.52117.12144.1726.1055.51-4.92
Funds from Operations-27.20-37.77-49.88-35.54-245.76-212.0597.68-152.36-64.78
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.1217.94-2.22-36.5281.9961.17-34.8626.7422.36
Cash from Operating Activities-32.32-19.83-52.11-72.06-163.77-150.8862.81-125.62-42.42
Capital Expenditures-0.99-0.01-0.05-0.16-6.81-4.64-1.16-1.77-2.18
Net Assets From Acquisitions0.000.000.000.000.000.00-37.330.000.00
Sale of Fixed Assets and Businesses0.000.050.060.000.000.000.000.000.00
Purchase or Sale of Investments13.26105.20-136.10-14.9974.87-108.129.2432.521.51
Purchase of Investments-0.21-50.09-245.99-99.91-1,100.04-1,578.35-361.04-19.39-4.53
Sale Or Maturity of Investments13.47155.29109.8984.931,174.911,470.23370.2851.916.05
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.002.10
Cash from Investing Activities12.27105.24-136.08-15.1568.07-112.76-29.2530.751.44
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.00-0.00
Change in Capital Stock0.7462.08-0.34-8.233.4892.09500.650.000.00
Repurchase of Common Pref Stock0.000.00-0.34-8.64-3.160.00-5.050.000.00
Sale of Common Pref Stock0.7462.080.000.416.6392.09505.700.000.00
Proceedsfrom Stock Options0.0061.880.000.006.63-12.21505.700.000.00
Issuance or Reduction of Debt, Net-0.67-0.82-0.59-0.572.820.00-7.2422.22203.62
Change in Long Term Debt0.000.000.000.000.000.000.0026.56206.49
Issuance of Long Term Debt0.000.000.000.000.000.000.0026.56206.49
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-4.200.000.000.000.005.05-0.1220.00
Other Financing Activities Uses0.00-4.200.000.000.000.000.00-0.120.00
Cash from Financing Activities0.0757.06-0.92-8.806.2992.09498.4622.10223.62
Exchange Rate Effect-0.050.280.575.1957.80-19.97-15.452.199.03
Net Change in Cash-20.04142.75-188.54-90.82-31.61-191.51516.57-70.57191.66
Free Cash Flow-33.31-19.84-52.16-72.22-170.58-155.5261.65-127.39-44.60
Price to Free Cash Flow------52.28--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12024S12023S22023S12022S1
Cash & Short Term Investments190.85-207.49322.14409.21585.88
Short Term Receivables5.64-0.002.530.0046.04
Inventories0.00-0.000.000.000.00
Other Current Assets1.52-22.994.1114.0912.61
Total Current Assets198.01-230.48329.47423.30644.53
Net Property, Plant & Equipment5.61-3.8911.6914.1124.20
Total Investments and Advances25.06-19.0010.016.2032.51
Intangible Assets---16.6538.6942.10
Other Assets2.87-0.460.601.142.30
Total Assets231.55-253.83368.43483.43745.65
Short Term Debt Incl. Current Port. of LT Debt1.28-0.747.317.896.35
Accounts Payable0.00-0.000.000.000.00
Other Current Liabilities24.65-13.2450.7583.3981.78
Total Current Liabilities25.92-13.9758.0791.2888.13
Long Term Debt3.18-3.223.262.819.16
Other Liabilities1.33-0.0064.8552.5148.43
Total Liabilities30.44-17.19126.17146.60145.72
Non-Equity Reserves0.00-0.000.000.000.00
Preferred Stock - Carrying Value0.00-0.000.000.000.00
Common Equity201.11-236.64242.26336.83599.92
Total Shareholders Equity201.11-236.64242.26336.83599.92
Accumulated Minority Interest0.00-0.000.000.000.00
Total Equity201.11-236.64242.26336.83599.92
Total Liabilities & Stockholders Equity231.55-253.83368.43483.43745.65
Book Value Per Share1.73-3.073.154.117.22
Tangible Book Value Per Share1.73-3.072.933.646.71
Price to Book Ratio0.50-0.530.460.731.57
Return on Assets---30.80---42.03
Return on Equity---39.59---49.37
Return on Invested Capital-18.57--10.24-38.99-32.83-26.52
Quick Ratio7.64-16.505.674.647.31
Current Ratio7.64-16.505.674.647.31

Cash flow, quarterly

Currency USD, millions
Metric2026S12024S12023S22023S12022S1
Net Income-37.95-----161.53
Depreciation0.60----5.19
Other Funds (Non Cash)10.14----59.48
Funds from Operations-27.20-----96.86
Extraordinary Item0.00----0.00
Changes in Working Capital-5.12----11.40
Cash from Operating Activities-32.32-----85.45
Capital Expenditures-0.99-----2.91
Net Assets From Acquisitions0.00----0.00
Sale of Fixed Assets and Businesses0.00----0.00
Purchase or Sale of Investments13.26----79.96
Purchase of Investments-0.21-----278.98
Sale Or Maturity of Investments13.47----358.94
Other Uses0.00----0.00
Other Sources0.00----0.00
Cash from Investing Activities12.27----77.05
Cash Dividends Paid0.00----0.00
Preferred Dividends (Cash Flow)0.00----0.00
Change in Capital Stock0.74----5.46
Repurchase of Common Pref Stock0.00----0.00
Sale of Common Pref Stock0.74----5.46
Proceedsfrom Stock Options0.00-----0.74
Issuance or Reduction of Debt, Net-0.67-----2.68
Change in Long Term Debt0.00----0.00
Issuance of Long Term Debt0.00----0.00
Reduction of Long Term Debt0.00----0.00
Net Financing Active Other Cash Flow0.00----0.00
Other Financing Activities Uses0.00----0.00
Cash from Financing Activities0.07----2.78
Exchange Rate Effect-0.05----34.52
Net Change in Cash-20.04----28.90
Free Cash Flow-33.31-----88.36

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.65%3.6M98.1M428.94K
2026-10-153.77%3.7M98.1M386.15K
2026-09-303.35%3.3M98.1M444.88K
2026-09-153.82%3.7M98.1M423.64K
2026-08-313.66%3.6M98.1M467.82K
2026-08-144.69%4.6M97.5M553.71K
2026-07-314.68%4.5M96.5M692.94K
2026-07-154.48%4.3M96.5M867.94K
2026-06-303.59%3.5M96.5M899.59K
2026-06-154.31%4.2M96.5M919.92K
2026-05-293.71%3.6M96.5M994.35K
2026-05-155.12%4.9M96.5M954.57K
2026-04-304.28%4.1M96.5M849.17K
2026-04-154.49%4.3M96.5M761.34K
2026-03-315.27%5.1M96.5M821.09K
2026-03-135.65%5.4M96.4M739.80K
2026-02-275.75%5.5M96.4M653.64K
2026-02-135.68%5.5M96.4M648.44K
2026-01-305.37%5.3M98.3M665.72K
2026-01-155.29%5.2M98.3M847.39K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.0520.1564100.000.894-0.0280.000
call5.000.004.900.000.0000.000.000.0000.0000.000
call7.500.004.900.000.0000.000.000.0000.0000.000
put2.501.052.200.900.00040.000.00-0.259-0.0320.000
put5.001.656.500.000.0000.000.00-0.847-0.0120.000
put7.504.109.000.000.0000.000.00-0.858-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13D/ASEC
2026-11-023Initial statement of beneficial ownership of securities2026-11-02SEC
2026-10-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-28SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-25SEC
2026-10-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-23SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-18144Filing for proposed sale of securities under Rule 144.SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-30SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-22SEC
2026-08-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-20SEC
2026-08-17S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-24SEC
2026-07-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-13SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-083Initial statement of beneficial ownership of securities2026-07-01SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-04SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090085.73K2
2026-08002.59K1
2026-07003.99K1
2026-060019.37K2
2026-050042.58K1
2026-04577.30K100
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HHLR ADVISORS, LTD.5.18%
MORGAN STANLEY3.17%
AIHC Capital Management Ltd2.49%
Siren, L.L.C.1.74%
MARSHALL WACE, LLP1.07%
Candriam S.C.A.0.98%
ADAGE CAPITAL PARTNERS GP, L.L.C.0.87%
TWO SIGMA INVESTMENTS, LP0.74%
RENAISSANCE TECHNOLOGIES LLC0.66%
BlackRock, Inc.0.59%

Funds

Fund% owned
iShares Biotechnology ETF0.51%
State Street(R) SPDR(R) Portfolio Emerging Markets ETF0.26%
ALPS Medical Breakthroughs ETF0.12%
Invesco NASDAQ Future Gen 200 ETF0.05%
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF0.04%
Fidelity Nasdaq Composite Index Fund0.04%
World ex U.S. Core Equity Portfolio0.02%
EMERGING MARKETS CORE EQUITY 2 PORTFOLIO0.02%
Emerging Markets Social Core Equity Portfolio0.01%
State Street(R) SPDR(R) S&P(R) China ETF0.01%

OakChart. NBP. Cached 15 minutes.